Return to Today's science sparks archives

2018-04-02

Figure 1. CT chest scan revealing progression of disease despite adjuvant chemotherapy and small pericardial effusion approximately 1 month prior to presentation.

Figure 1. CT chest scan revealing progression of disease despite adjuvant chemotherapy and small pericardial effusion approximately 1 month prior to presentation.
  • Chen LL, Finan M, Mead E, Halpern NA

  • Chest. 2018 Mar;153(3):e49-e52.

2018-04-03

Figure 1. Arterial and venous thrombosis during follow-up in patients with MPNs versus matched control participants.

Figure 1. Arterial and venous thrombosis during follow-up in patients with MPNs versus matched control participants.
  • Hultcrantz M, Björkholm M, Dickman PW, Landgren O, Derolf ÅR, Kristinsson SY, Andersson TML

  • Ann Intern Med. 2018 Mar 6;168(5):317-325.

2018-04-04

Figure 1.Chemoenzymatic approach used to create the IEADC.

Figure 1.Chemoenzymatic approach used to create the IEADC.
  • Adumeau P, Vivier D, Sharma SK, Wang J, Zhang T, Chen A, Agnew BJ, Zeglis BM

  • Mol Pharm. 2018 Mar 5;15(3):892-898.

2018-04-05

Fig 1. CAR structure: First generation CARs contain an antigen recognition domain fused with an intracellular activation domain.

Fig 1. CAR structure: First generation CARs contain an antigen recognition domain fused with an intracellular activation domain.
  • Chen N, Li X, Chintala NK, Tano ZE, Adusumilli PS

  • Curr Opin Immunol. 2018 Mar 16;51:103-110.

2018-04-06

Fig. 2 Gene expression studies on lung cancer subtypes.

Fig. 2 Gene expression studies on lung cancer subtypes.
  • George J, Walter V, Peifer M, Alexandrov LB, Seidel D, Leenders F, Maas L, Müller C, Dahmen I, Delhomme TM, Ardin M, Leblay N, Byrnes G, Sun R, De Reynies A, McLeer-Florin A, Bosco G, Malchers F, Menon R, Altmüller J, Becker C, Nürnberg P, Achter V, Lang U, Schneider PM, Bogus M, Soloway MG, Wilkerson MD, Cun Y, McKay JD, Moro-Sibilot D, Brambilla CG, Lantuejoul S, Lemaitre N, Soltermann A, Weder W, Tischler V, Brustugun OT, Lund-Iversen M, Helland Å, Solberg S, Ansén S, Wright G, Solomon B, Roz L, Pastorino U, Petersen I, Clement JH, Sänger J, Wolf J, Vingron M, Zander T, Perner S, Travis WD, Haas SA, Olivier M, Foll M, Büttner R, Hayes DN, Brambilla E, Fernandez-Cuesta L, Thomas RK

  • Nat Commun. 2018 Mar 13;9(1):1048.
Open Access button

2018-04-09

Figure 5. CIN generates cytosolic DNA.

Figure 5. CIN generates cytosolic DNA.
  • Bakhoum SF, Ngo B, Laughney AM, Cavallo JA, Murphy CJ, Ly P, Shah P, Sriram RK, Watkins TBK, Taunk NK, Duran M, Pauli C, Shaw C, Chadalavada K, Rajasekhar VK, Genovese G, Venkatesan S, Birkbak NJ, McGranahan N, Lundquist M, LaPlant Q, Healey JH, Elemento O, Chung CH, Lee NY, Imielenski M, Nanjangud G, Pe'er D, Cleveland DW, Powell SN, Lammerding J, Swanton C, Cantley LC

  • Nature. 2018 Jan 25;553(7689):467-472.

2018-04-11

Figure 1. The formation of androgen receptor messenger RNA (mRNA) and its expression in higher order cognitive brain centers
are illustrated.

Figure 1. The formation of androgen receptor messenger RNA (mRNA) and its expression in higher order cognitive brain centers are illustrated.
  • McHugh DJ, Root JC, Nelson CJ, Morris MJ

  • Cancer. 2018 Apr 1;124(7):1326-1334.

2018-04-12

Fig 7. Observation of patterns associated with TCGA pan-urologic genomic subtypes in an external multi-cancer expression profiling data set.

Fig 7. Observation of patterns associated with TCGA pan-urologic genomic subtypes in an external multi-cancer expression profiling data set.
  • Chen F, Zhang Y, Bossé D, Lalani AA, Hakimi AA, Hsieh JJ, Choueiri TK, Gibbons DL, Ittmann M, Creighton CJ

  • Nat Commun. 2017 Aug 4;8(1):199.
Open Access button

2018-04-13

Figure 1. Roles of the mRNA Decapping Scavenger Enzyme DCPS in the Life Cycle of mRNA.

Figure 1. Roles of the mRNA Decapping Scavenger Enzyme DCPS in the Life Cycle of mRNA.
  • Yoshimi A, Abdel-Wahab O

  • Cancer Cell. 2018 Mar 12;33(3):339-341.

2018-04-16

Fig. 1. ROI placement is shown on selected central slice to compute fat/parotid CNR.

Fig. 1. ROI placement is shown on selected central slice to compute fat/parotid CNR.
  • Sarkar SN, Hackney DB, Greenman RL, Vachha BA, Johnson EA, Nagle S, Moonis,G

  • European Journal of Radiology, May 2018, Vol.102, pp.202-207.

2018-04-17

Figure 1. Inverse electron demand Diels−Alder (IEDDA) reaction between trans-cyclooctene and tetrazine.

Figure 1. Inverse electron demand Diels−Alder (IEDDA) reaction between trans-cyclooctene and tetrazine.
  • Membreno R, Cook BE, Fung K, Lewis JS, Zeglis BM

  • Mol Pharm. 2018 Apr 2;15(4):1729-1734.

2018-04-18

Fig 4. Evolutionarily conserved rRNA variants in functionally important centers of the human ribosome.

Fig 4. Evolutionarily conserved rRNA variants in functionally important centers of the human ribosome.
  • Parks MM, Kurylo CM, Dass RA, Bojmar L, Lyden D, Vincent CT, Blanchard SC

  • Sci Adv. 2018 Feb 28;4(2):eaao0665
Open Access button

2018-04-19

FIG 2. Resident cytolytic type 1 innate lymphocytes in the tumor microenvironment.

FIG 2. Resident cytolytic type 1 innate lymphocytes in the tumor microenvironment.
  • Nixon BG, Li MO

  • J Immunol. 2018 Jan 15;200(2):408-414.

2018-04-20

FIGURE 4. ACTB-GLI1 and novel PTCH1-GLI1 gene fusion structure and molecular correlates.

FIGURE 4. ACTB-GLI1 and novel PTCH1-GLI1 gene fusion structure and molecular correlates.
  • Antonescu CR, Agaram NP, Sung YS, Zhang L, Swanson D, Dickson BC

  • Am J Surg Pathol. 2018 Apr;42(4):553-560.

2018-04-23

Fig 1. Scanning electron microscopic analysis of glomerular vascular corrosion casts reveals an increase in intussusceptive events and in vascular diameter.

Fig 1. Scanning electron microscopic analysis of glomerular vascular corrosion casts reveals an increase in intussusceptive events and in vascular diameter.
  • Farber G, Hurtado R, Loh S, Monette S, Mtui J, Kopan R, Quaggin S, Meyer-Schwesinger C, Herzlinger D, Scott RP, Blobel CP

  • Angiogenesis. 2018 May;21(2):335-347.

2018-04-24

Fig 2. Copy number abnormalities (CNAs) in xenografts.

Fig 2. Copy number abnormalities (CNAs) in xenografts.
  • Cybulska P, Stewart JM, Sayad A, Virtanen C, Shaw PA, Clarke B, Stickle N, Bernardini MQ, Neel BG

  • Am J Pathol. 2018 May;188(5):1120-1131.

2018-04-25

Fig 2. From superior to inferior, images of T1-weighted postcontrast MRI, Ktrans, and Ve before (left) and 8 weeks after (right) SRS to a midline cerebellar lesion.

Fig 2. From superior to inferior, images of T1-weighted postcontrast MRI, Ktrans, and Ve before (left) and 8 weeks after (right) SRS to a midline cerebellar lesion.
  • Taunk NK, Oh JH, Shukla-Dave A, Beal K, Vachha B, Holodny A, Hatzoglou V

  • Neuro Oncol. 2018 Mar 27;20(4):567-575.

2018-04-26

Figure 1. Ink used to define the margin surface can be seen at various distances from the tumor edge.

Figure 1. Ink used to define the margin surface can be seen at various distances from the tumor edge.
  • Pilewskie M, Morrow M

  • Cancer. 2018 Apr 1;124(7):1335-1341.

2018-04-27

Fig. 3. Kaplan-Meier curves by income (1 ≤$50,000, 4≥ $150,000).

Fig. 3. Kaplan-Meier curves by income (1 ≤$50,000, 4≥ $150,000).
  • Cowan RA, Tseng J, Ali N, Dearie H, Murthy V, Gennarelli RL, Iasonos A, Abu-Rustum NR, Chi DS, Long Roche KC, Brown CL

  • Gynecol Oncol. 2018 Apr;149(1):43-48.

2018-04-30

Fig 3. β2-microglobulin (β2M), major histocompatibility complex (MHC) class I and MHC class II expression.

Fig 3. β2-microglobulin (β2M), major histocompatibility complex (MHC) class I and MHC class II expression.
  • Roemer MGM, Redd RA, Cader FZ, Pak CJ, Abdelrahman S, Ouyang J, Sasse S, Younes A, Fanale M, Santoro A, Zinzani PL, Timmerman J, Collins GP, Ramchandren R, Cohen JB, De Boer JP, Kuruvilla J, Savage KJ, Trneny M, Ansell S, Kato K, Farsaci B, Sumbul A, Armand P, Neuberg DS, Pinkus GS, Ligon AH, Rodig SJ, Shipp MA

  • J Clin Oncol. 2018 Apr 1;36(10):942-950.

2018-05-01

Fig 2. DH270.6-Env V3 loop structure.

Fig 2. DH270.6-Env V3 loop structure.
  • Fera D, Lee MS, Wiehe K, Meyerhoff RR, Piai A, Bonsignori M, Aussedat B, Walkowicz WE, Ton T, Zhou JO, Danishefsky S, Haynes BF, Harrison SC

  • Nat Commun. 2018 Mar 16;9(1):1111.
Open Access button

2018-05-02

Fig 4. Invasive ductal carcinoma Grade 1 seen in B-mode ultrasound as an 8 mm, hypoechoic, circumscribed lesion, which was initially classified as BI-RADS 3.

Fig 4. Invasive ductal carcinoma Grade 1 seen in B-mode ultrasound as an 8 mm, hypoechoic, circumscribed lesion, which was initially classified as BI-RADS 3.
  • Kapetas P, Clauser P, Woitek R, Pinker K, Bernathova M, Helbich TH, Baltzer PA

  • Sci Rep. 2018 Feb 26;8(1):3583.
Open Access button

2018-05-03

Fig 1. Conceptual model linking obesity to breast cancer.

Fig 1. Conceptual model linking obesity to breast cancer.
  • Argolo DF, Hudis CA, Iyengar NM

  • Curr Oncol Rep. 2018 Apr 11;20(6):47.

2018-05-04

Fig 5. Genetic Aberrations Targeting Oncogenic Signaling Pathways in DLBCL. Shown is the prevalence of putative gain-of-function or loss-of-function genetic aberrations targeting genes in each indicated oncogenic signaling category. The prevalence of genetic aberrations is indicated by the color scale shown. Genetic aberrations included for each gene are indicated in Figure S5B in Supplementary Appendix 1. BCR denotes B-cell receptor, CBM complex CARD11–BCL10–MALT1 signaling adaptor complex, mRNA messenger RNA, and NF-κB nuclear factor κB.

Fig 5. Genetic Aberrations Targeting Oncogenic Signaling Pathways in DLBCL. Shown is the prevalence of putative gain-of-function or loss-of-function genetic aberrations targeting genes in each indicated oncogenic signaling category. The prevalence of genetic aberrations is indicated by the color scale shown. Genetic aberrations included for each gene are indicated in Figure S5B in Supplementary Appendix 1. BCR denotes B-cell receptor, CBM complex CARD11–BCL10–MALT1 signaling adaptor complex, mRNA messenger RNA, and NF-κB nuclear factor κB.
  • Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, Roulland S, Kasbekar M, Young RM, Shaffer AL, Hodson DJ, Xiao W, Yu X, Yang Y, Zhao H, Xu W, Liu X, Zhou B, Du W, Chan WC, Jaffe ES, Gascoyne RD, Connors JM, Campo E, Lopez-Guillermo A, Rosenwald A, Ott G, Delabie J, Rimsza LM, Tay Kuang Wei K, Zelenetz AD, Leonard JP, Bartlett NL, Tran B, Shetty J, Zhao Y, Soppet DR, Pittaluga S, Wilson WH, Staudt LM

  • N Engl J Med. 2018 Apr 12;378(15):1396-1407.

2018-05-07

Fig 1. TGF-β Inhibition Induces Tumor T Cell Infiltration and Potentiates Response to Immune Checkpoint Therapy

Expression of a fibroblast TGF-β response signature (F-TBRS) in peritumoral fibroblasts leads to T cell sequestration away from the tumor mass. In the absence of physical proximity between cytototoxic T cells and tumor cells, immune checkpoint blockade with PD-1/PD-L1 inhibitors is ineffective. Pharmacological inhibition of TGF-β reverses such immune exclusion and facilitates CD8+ T cell infiltration into tumors. Combination of TGF-β inhibition with immune checkpoint blockade maximizes tumor regression with many tumor-bearing mice exhibiting a complete response. These findings lay the foundation for combination clinical trials in cancer patients whose tumors exhibit an immune excluded phenotype.

Fig 1. TGF-β Inhibition Induces Tumor T Cell Infiltration and Potentiates Response to Immune Checkpoint Therapy Expression of a fibroblast TGF-β response signature (F-TBRS) in peritumoral fibroblasts leads to T cell sequestration away from the tumor mass. In the absence of physical proximity between cytototoxic T cells and tumor cells, immune checkpoint blockade with PD-1/PD-L1 inhibitors is ineffective. Pharmacological inhibition of TGF-β reverses such immune exclusion and facilitates CD8+ T cell infiltration into tumors. Combination of TGF-β inhibition with immune checkpoint blockade maximizes tumor regression with many tumor-bearing mice exhibiting a complete response. These findings lay the foundation for combination clinical trials in cancer patients whose tumors exhibit an immune excluded phenotype.
  • Ganesh K, Massagué J

  • Immunity. 2018 Apr 17;48(4):626-628.

2018-05-08

Fig 2. Kaplan-Meier estimates of progression-free survival and overall survival. (A) Blinded independent central review of progression-free survival. (B) Overall survival. Population: full analysis set, data cutoff: May 15, 2015. Crosses denote censored observations. Overall survival data are immature, with 34 events (35%) and 14 events (44%) in the selumetinib plus dacarbazine and placebo plus dacarbazine groups, respectively. DTIC, dacarbazine; HR, hazard ratio; Pbo, placebo; Sel, selumetinib.

Fig 2. Kaplan-Meier estimates of progression-free survival and overall survival. (A) Blinded independent central review of progression-free survival. (B) Overall survival. Population: full analysis set, data cutoff: May 15, 2015. Crosses denote censored observations. Overall survival data are immature, with 34 events (35%) and 14 events (44%) in the selumetinib plus dacarbazine and placebo plus dacarbazine groups, respectively. DTIC, dacarbazine; HR, hazard ratio; Pbo, placebo; Sel, selumetinib.
  • Carvajal RD, Piperno-Neumann S, Kapiteijn E, Chapman PB, Frank S, Joshua AM, Piulats JM, Wolter P, Cocquyt V, Chmielowski B, Evans TRJ, Gastaud L, Linette G, Berking C, Schachter J, Rodrigues MJ, Shoushtari AN, Clemett D, Ghiorghiu D, Mariani G, Spratt S, Lovick S, Barker P, Kilgour E, Lai Z, Schwartz GK, Nathan P

  • J Clin Oncol. 2018 Apr 20;36(12):1232-1239.

2018-05-09

Figure 2. Chemical cross-linking and mass spectrometry reveals nucleoporin connectivity in the NPC.

Figure 2. Chemical cross-linking and mass spectrometry reveals nucleoporin connectivity in the NPC.
  • Kim SJ, Fernandez-Martinez J, Nudelman I, Shi Y, Zhang W, Raveh B, Herricks T, Slaughter BD, Hogan JA, Upla P, Chemmama IE, Pellarin R, Echeverria I, Shivaraju M, Chaudhury AS, Wang J, Williams R, Unruh JR, Greenberg CH, Jacobs EY, Yu Z, de la Cruz MJ, Mironska R, Stokes DL, Aitchison JD, Jarrold MF, Gerton JL, Ludtke SJ, Akey CW, Chait BT, Sali A, Rout MP

  • Nature. 2018 Mar 22;555(7697):475-482.

2018-05-10

Fig 1. RP-donor mutants of Ubx and kuz are strong loss-of-function alleles.

Fig 1. RP-donor mutants of Ubx and kuz are strong loss-of-function alleles.
  • Joseph B, Kondo S, Lai EC

  • Nat Struct Mol Biol. 2018 Apr 9.

2018-05-11

Fig 1.(top) Chemical structure of 1. (bottom) Overlay of 1 (teal):DCN1 (electrostatic potential surface) (PDB 6BG5)(1) and UBE2MNAc (magenta):DCN1 (PDB 3TDU) X-ray co-crystal structures, highlighting regions targeted for optimization.(1)

Fig 1.(top) Chemical structure of 1. (bottom) Overlay of 1 (teal):DCN1 (electrostatic potential surface) (PDB 6BG5)(1) and UBE2MNAc (magenta):DCN1 (PDB 3TDU) X-ray co-crystal structures, highlighting regions targeted for optimization.(1)
  • Hammill JT, Bhasin D, Scott DC, Min J, Chen Y, Lu Y, Yang L, Kim HS, Connelly MC, Hammill C, Holbrook G, Jeffries C, Singh B, Schulman BA, Guy RK

  • J Med Chem. 2018 Apr 12;61(7):2694-2706.

2018-05-14

Fig. 1. Transversal cross section (left) and sagittal plan (right) through the PTV of an example patient treated on the IMRT protocol with the bootstrap variance of the dose within the CTV shown in color-wash. It is apparent that the variance was larger within the CTV close to the rectum, which stems from a steep dose-gradient in that region as well as the magnitude of the positioning uncertainty in this direction

Fig. 1. Transversal cross section (left) and sagittal plan (right) through the PTV of an example patient treated on the IMRT protocol with the bootstrap variance of the dose within the CTV shown in color-wash. It is apparent that the variance was larger within the CTV close to the rectum, which stems from a steep dose-gradient in that region as well as the magnitude of the positioning uncertainty in this direction
  • Munck Af Rosenschold, Zelefsky MJ, Apte AP, Jackson A, Oh JH, Shulman E, Desai N, Hunt M, Ghadjar P, Yorke E, Deasy JO

  • Radiat Oncol. 2018 Apr 12;13(1):64.
Open Access button

2018-05-15

Figure 3. Induction of PD-L1 in NDV-treated and distant tumors.

Figure 3. Induction of PD-L1 in NDV-treated and distant tumors.
  • Zamarin D, Ricca JM, Sadekova S, Oseledchyk A, Yu Y, Blumenschein WM, Wong J, Gigoux M, Merghoub T, Wolchok JD

  • J Clin Invest. 2018 Apr 2;128(4):1413-1428.

2018-05-16

Figure 1
In a positively curved space the distance between the end points of tangent vectors ω and ω′ is less than δ. Curvature (K) quantifies this difference.

Figure 1 In a positively curved space the distance between the end points of tangent vectors ω and ω′ is less than δ. Curvature (K) quantifies this difference.
  • Pouryahya M, Oh JH, Mathews JC, Deasy JO, Tannenbaum AR

  • Sci Rep. 2018 Apr 23;8(1):6402.
Open Access button

2018-05-17

Figure 1. Outline of Experimental Approach and Analyses.

Figure 1. Outline of Experimental Approach and Analyses.
  • Shulman AS, Tsou MF

  • Dev Cell. 2017 Dec 18;43(6):653-655.

2018-05-18

Figure 4. Targeted analysis of proinflammatory eicosanoids.

Figure 4. Targeted analysis of proinflammatory eicosanoids.
  • Laiakis EC, Pannkuk EL, Chauthe SK, Wang YW, Lian M, Mak TD, Barker CA, Astarita G, Fornace AJ Jr

  • J Proteome Res. 2017 Oct 6;16(10):3805-3815.

2018-05-21

Fig 3. LnCAP cells form 3D spheroids in extracellular matrix that are amenable to hyperpolarized MRS. A, LnCAP cells grown in 1:1 alginate:Matrigel form distinct organoids as visualized under light microscopy (left), that contain multiple DAPI-stained nuclei (middle) and stain positive with calcein-AM, a fluorescent marker of cell viability (right). B, Spheroid cross-section distribution peaks at approximately 200 μm. C, For hyperpolarized experiments, LnCAP cells seeded in matrix were deposited into porous hollow fibers, D, Direct deposition of the hollow fiber in a 5-mm NMR tube followed by injection of 5 mmol/L HP [1-13C] pyruvate resulted in rapid formation of [1-13C] lactate.

Fig 3. LnCAP cells form 3D spheroids in extracellular matrix that are amenable to hyperpolarized MRS. A, LnCAP cells grown in 1:1 alginate:Matrigel form distinct organoids as visualized under light microscopy (left), that contain multiple DAPI-stained nuclei (middle) and stain positive with calcein-AM, a fluorescent marker of cell viability (right). B, Spheroid cross-section distribution peaks at approximately 200 μm. C, For hyperpolarized experiments, LnCAP cells seeded in matrix were deposited into porous hollow fibers, D, Direct deposition of the hollow fiber in a 5-mm NMR tube followed by injection of 5 mmol/L HP [1-13C] pyruvate resulted in rapid formation of [1-13C] lactate.
  • Tee SS, Suster I, Truong S, Jeong S, Eskandari R, DiGialleonardo V, Alvarez JA, Aldeborgh HN, Keshari KR

  • Mol Cancer Res. 2018 Mar;16(3):453-460.

2018-05-22

Fig. 1 Percentage of patients who reported decreased physical activity since cancer diagnosis by cancer type (N = 629).

Fig. 1 Percentage of patients who reported decreased physical activity since cancer diagnosis by cancer type (N = 629).
  • Romero SAD, Jones L, Bauml JM, Li QS, Cohen RB, Mao JJ

  • Support Care Cancer. 2018 Apr 19.

2018-05-23

Fig 5. Ex vivo H&E and autoradiographic imaging of HEK293-NK1R (A, B, E, and G) and HEK293-WT (C, D, F, and H) xenografts with [64Cu]NK1R-NOTA. [64Cu]NK1R-NOTA showed a significantly higher level of uptake in NK1R-transduced tissue (A and E) than in nontransduced tissue (C and F). Necrotic regions identified by H&E staining (B, D, G, and H) demonstrated only a very low level of binding of [64Cu]NK1R-NOTA (A, C, E, and F).

Fig 5. Ex vivo H&E and autoradiographic imaging of HEK293-NK1R (A, B, E, and G) and HEK293-WT (C, D, F, and H) xenografts with [64Cu]NK1R-NOTA. [64Cu]NK1R-NOTA showed a significantly higher level of uptake in NK1R-transduced tissue (A and E) than in nontransduced tissue (C and F). Necrotic regions identified by H&E staining (B, D, G, and H) demonstrated only a very low level of binding of [64Cu]NK1R-NOTA (A, C, E, and F).
  • Zhang H, Kanduluru AK, Desai P, Ahad A, Carlin S, Tandon N, Weber WA, Low PS

  • Bioconjug Chem. 2018 Apr 18;29(4):1319-1326.

2018-05-24

Figure 2. Reduction of cilia number in Rsg1
mutants.

Figure 2. Reduction of cilia number in Rsg1 mutants.
  • Agbu SO, Liang Y, Liu A, Anderson KV

  • J Cell Biol. 2018 Jan 2;217(1):413-427.

2018-05-25

Figure 3. Planar (left) and maximum intensity projection (right) PET images of athymic nude mice bearing A33 antigen-expressing SW1222 colorectal cancer xenografts (white arrow) following the injection of 89Zr-DFO-PODS-huA33 and 89Zr-DFO-mal-huA33 (140 μCi, 60–65 μg). The coronal slices intersect the center of the tumors.

Figure 3. Planar (left) and maximum intensity projection (right) PET images of athymic nude mice bearing A33 antigen-expressing SW1222 colorectal cancer xenografts (white arrow) following the injection of 89Zr-DFO-PODS-huA33 and 89Zr-DFO-mal-huA33 (140 μCi, 60–65 μg). The coronal slices intersect the center of the tumors.
  • Adumeau P, Davydova M, Zeglis BM

  • Bioconjug Chem. 2018 Apr 18;29(4):1364-1372.

2018-05-29

Figure 2 Graph showing the percentage of different histology types in the original and validation cohorts.

Figure 2 Graph showing the percentage of different histology types in the original and validation cohorts.
  • Hay A, Migliacci J, Zanoni DK, Patel S, Yu C, Kattan MW, Ganly I

  • Head Neck. 2018 May;40(5):1008-1015.

2018-05-30

Figure 2. The graph demonstrates the percentage of each histologic subtype in the primary and matched metastatic tumor for each case.

Figure 2. The graph demonstrates the percentage of each histologic subtype in the primary and matched metastatic tumor for each case.
  • Takahashi Y, Eguchi T, Lu S, Downey RJ, Jones DR, Travis WD, Adusumilli PS

  • Am J Respir Crit Care Med. 2018 Mar 15;197(6):816-818.

2018-05-31

Fig. 1. Biophysical interaction of nanosilicates and hMSCs.

Fig. 1. Biophysical interaction of nanosilicates and hMSCs.
  • Carrow JK, Cross LM, Reese RW Jaiswal MK, Gregory CA, Kaunas R, Singh I, Gaharwar AK

  • Proc Natl Acad Sci U S A. 2018 Apr 24;115(17)
Open Access button

2018-06-01

Fig 1. Representative images of segmented brain volumes in a study participant. This set of images shows segmented brain structures in sagittal, axial, and coronal planes (a, b, c).

Fig 1. Representative images of segmented brain volumes in a study participant. This set of images shows segmented brain structures in sagittal, axial, and coronal planes (a, b, c).
  • Chen BT, Sethi SK, Jin T, Patel SK, Ye N, Sun CL, Rockne RC, Haacke EM, Root JC, Saykin AJ, Ahles TA, Holodny AI, Prakash N, Mortimer J, Waisman J, Yuan Y, Somlo G, Li D, Yang R, Tan H, Katheria V, Morrison R, Hurria A

  • Breast Cancer Res. 2018 May 2;20(1):38.
Open Access button

2018-06-04

Fig 2.  Cumulative incidence of retinal reattachment by time (months).

Fig 2. Cumulative incidence of retinal reattachment by time (months).
  • Rowlands MA, Mondesire-Crump I, Levin A, Mauguen A, Francis JH, Dunkel IJ, Brodie SE, Gobin YP, Abramson DH

  • PLoS One. 2018 Apr 26;13(4):e0195395.
Open Access button

2018-06-05

Fig 1. NPC Assembly Appears Unaltered in Nup133-Deficient mESCs.

Fig 1. NPC Assembly Appears Unaltered in Nup133-Deficient mESCs.
  • Souquet B, Freed E, Berto A, Andric V, Audugé N, Reina-San-Martin B, Lacy E, Doye V

  • Cell Rep. 2018 May 22;23(8):2443-2454.
Open Access button

2018-06-06

Fig 4. SNP-array analysis of MTSCC, PRCC, and IND cases.

Fig 4. SNP-array analysis of MTSCC, PRCC, and IND cases.
  • Ren Q, Wang L, Al-Ahmadie HA, Fine SW, Gopalan A, Sirintrapun SJ, Tickoo SK, Reuter VE, Chen YB.

  • Am J Surg Pathol. 2018 Jun;42(6):767-777.

2018-06-07

Fig 1. Schematic of the representation of Gag binding in the model.

Fig 1. Schematic of the representation of Gag binding in the model.
  • Tomasini MD, Johnson DS, Mincer JS, Simon SM

  • PLoS One. 2018 Apr 20;13(4):e0196133.
Open Access button

2018-06-08

Exhibit 2. Predicted increases in costs per quality-adjusted life-year (QALY) gained if coinsurance for colorectal cancer screening were waived, by percentage-point increase in adherence to screening, diagnostic follow-up, and surveillance

Exhibit 2. Predicted increases in costs per quality-adjusted life-year (QALY) gained if coinsurance for colorectal cancer screening were waived, by percentage-point increase in adherence to screening, diagnostic follow-up, and surveillance
  • Peterse EFP, Meester RGS, Gini A, Doubeni CA, Anderson DS, Berger FG, Zauber AG, Lansdorp-Vogelaar I

  • Health Aff (Millwood). 2017 Dec;36(12):2151-2159.

2018-06-11

Figure 1. Hepatic Arterial Infusion Pump Placement.

Figure 1. Hepatic Arterial Infusion Pump Placement.
  • Italiano D

  • Clin J Oncol Nurs. 2018 Jun 1;22(3):340-346.

2018-06-12

Fig 1. CTLA-4 and PD-1/PD-L1 checkpoint interaction between T cell and tumor. TCR T cell receptor, MHC major histocompatibility complex, CTLA-4 cytotoxic T lymphocyte antigen-4, PD1 programmed cell death protein 1, PD-L1 PD1 ligand

Fig 1. CTLA-4 and PD-1/PD-L1 checkpoint interaction between T cell and tumor. TCR T cell receptor, MHC major histocompatibility complex, CTLA-4 cytotoxic T lymphocyte antigen-4, PD1 programmed cell death protein 1, PD-L1 PD1 ligand
  • Lyons TG, Dickler MN, Comen EE

  • Curr Oncol Rep. 2018 Apr 30;20(7):51.

2018-06-13

Fig 2. Enrichment of IpA sites at the start of transcription units.

Fig 2. Enrichment of IpA sites at the start of transcription units.
  • Singh I, Lee SH, Sperling AS, Samur MK, Tai YT, Fulciniti M, Munshi NC, Mayr C, Leslie CS

  • Nat Commun. 2018 Apr 30;9(1):1716.

2018-06-14

Fig 2. (A) In vitro abundances of Aeromonas when mixed with V. cholerae strains, determined from spotting liquid-cultured pairs of strains onto agar-supported membranes at 3 h after mixing. Comparison of each Aeromonas abundance distribution with that of the V. cholerae T6SS−-challenged dataset gives P < 0.001 for a two-sample KS test, except for the V. cholerae T6SS− Imm−, for which P = 0.3. (B) Schematic diagram of the protocol used to characterize Aeromonas–Vibrio interactions in vivo. Aeromonas (magenta) is allowed to colonize at 4 dpf, followed by inoculation of V. cholerae (orange) strains into the surrounding water at 5 dpf. Imaging and/or dissections and serial plating occur at 6 dpf. (C) Histogram of Aeromonas abundances in the larval gut 24 h after potential invasion by V. cholerae strains. The peak abundances are roughly 103 CFU per gut when Aeromonas is followed by T6SS− Imm− and T6SS−, 102 when followed by wild-type, and 0 when followed by T6SS+. Comparison of each Aeromonas population distribution with that of the T6SS− Imm−-challenged distribution using a two sample KS test gives P = 0.46, 0.045, and 0.0066 for challenge by the T6SS−, T6SSWT, and T6SS+ V. cholerae strains, respectively. (D and E) Maximum intensity projections of a 3D light sheet image stack of Aeromonas in the larval gut at 24 h after invasion by T6SS− Imm− (D) and T6SS+ V. cholerae (E) with the boundaries of the gut lumen roughly indicated by yellow dotted lines. (Scale bar: 50 μm.)

Fig 2. (A) In vitro abundances of Aeromonas when mixed with V. cholerae strains, determined from spotting liquid-cultured pairs of strains onto agar-supported membranes at 3 h after mixing. Comparison of each Aeromonas abundance distribution with that of the V. cholerae T6SS−-challenged dataset gives P < 0.001 for a two-sample KS test, except for the V. cholerae T6SS− Imm−, for which P = 0.3. (B) Schematic diagram of the protocol used to characterize Aeromonas–Vibrio interactions in vivo. Aeromonas (magenta) is allowed to colonize at 4 dpf, followed by inoculation of V. cholerae (orange) strains into the surrounding water at 5 dpf. Imaging and/or dissections and serial plating occur at 6 dpf. (C) Histogram of Aeromonas abundances in the larval gut 24 h after potential invasion by V. cholerae strains. The peak abundances are roughly 103 CFU per gut when Aeromonas is followed by T6SS− Imm− and T6SS−, 102 when followed by wild-type, and 0 when followed by T6SS+. Comparison of each Aeromonas population distribution with that of the T6SS− Imm−-challenged distribution using a two sample KS test gives P = 0.46, 0.045, and 0.0066 for challenge by the T6SS−, T6SSWT, and T6SS+ V. cholerae strains, respectively. (D and E) Maximum intensity projections of a 3D light sheet image stack of Aeromonas in the larval gut at 24 h after invasion by T6SS− Imm− (D) and T6SS+ V. cholerae (E) with the boundaries of the gut lumen roughly indicated by yellow dotted lines. (Scale bar: 50 μm.)
  • Logan SL, Thomas J, Yan J, Baker RP, Shields DS, Xavier JB, Hammer BK, Parthasarathy R

  • Proc Natl Acad Sci U S A. 2018 Apr 17;115(16):E3779-E3787.

2018-06-15

Fig. 1. Overview of the scvis method.

Fig. 1. Overview of the scvis method.
  • Ding J, Condon A, Shah SP

  • Nat Commun. 2018 May 21;9(1):2002.

2018-06-18

Fig. 1. Acute biodistribution of [223Ra]RaCl2 in healthy C57Bl/6 mice.

Fig. 1. Acute biodistribution of [223Ra]RaCl2 in healthy C57Bl/6 mice.
  • Jiang W, Ulmert D, Simons BW, Abou DS, Thorek DLJ

  • Nucl Med Biol. 2018 May 8;62-63:1-8.

2018-06-19

Fig 1. Comparison of therapeutic particle energies, particle ranges, LET, and DNA damage potencies.

Fig 1. Comparison of therapeutic particle energies, particle ranges, LET, and DNA damage potencies.
  • Poty S, Francesconi LC, McDevitt MR, Morris MJ, Lewis JS

  • J Nucl Med. 2018 Jun;59(6):878-884.

2018-06-20

Fig 1. Summed whole-body (WB) and serum biologic clearance data for 89Zr-pertuzumab in 6 patients.

Fig 1. Summed whole-body (WB) and serum biologic clearance data for 89Zr-pertuzumab in 6 patients.
  • Ulaner GA, Lyashchenko SK, Riedl C, Ruan S, Zanzonico PB, Lake D, Jhaveri K, Zeglis B, Lewis JS, O'Donoghue JA

  • J Nucl Med. 2018 Jun;59(6):900-906.

2018-06-21

Figure 1. Ascorbates as redox imaging probes.

Figure 1. Ascorbates as redox imaging probes.
  • Qin H, Carroll VN, Sriram R, Villanueva-Meyer JE, von Morze C, Wang ZJ, Mutch CA, Keshari KR, Flavell RR, Kurhanewicz J, Wilson DM

  • Sci Rep. 2018 May 21;8(1):7928.
Open Access button

2018-06-22

Fig 2. Plot of absolute FKSI scores over time(intent-to-treat population).

Fig 2. Plot of absolute FKSI scores over time(intent-to-treat population).
  • Cella D, Escudier B, Tannir NM, Powles T, Donskov F, Peltola K, Schmidinger M, Heng DYC, Mainwaring PN, Hammers HJ, Lee JL, Roth BJ, Marteau F, Williams P, Baer J, Mangeshkar M, Scheffold C, Hutson TE1, Pal S, Motzer RJ, Choueiri TK

  • J Clin Oncol. 2018 Mar 10;36(8):757-764.

2018-06-25

Fig 1. Cell survival curves as a function of absorbed dose for high and low linear energy transfer (LET) emitters.

Fig 1. Cell survival curves as a function of absorbed dose for high and low linear energy transfer (LET) emitters.
  • McDevitt MR, Sgouros G, Sofou S

  • Annu Rev Biomed Eng. 2018 Jun 4;20:73-93.

2018-06-26

Fig. 1. cMET IHC staining.

Fig. 1. cMET IHC staining.
  • Wang M, Liang L, Lei X, Multani A, Meric-Bernstam F, Tripathy D, Wu Y, Chen H, Zhang H

  • Ann Diagn Pathol. 2018 May 3;35:69-76.

2018-06-27

Fig 1. Ari-1 Interacts with Parkin to Facilitate Myonuclear Positioning

(A) In a wild-type larval muscle, myonuclear positioning is facilitated by the interaction of Ari-1 and Parkin, members of E3 ubiquitin ligase family, which regulate ubiquitination and turnover of Koi, one component of the LINC complex (Tan et al., 2018). (B) In an ari-1 null larval muscle, Parkin forms a dimer and is able to partially regulate myonuclear positioning. (C) In larvae with a missense mutation in ari-1, mutant Ari-1 binds strongly to Parkin—and perhaps to more than one Parkin—hindering the ability of both Ari-1 and Parkin to ubiquitinate Koi. This results in aberrant myonuclear positioning, nuclear clustering, and defective nuclear morphology.

Fig 1. Ari-1 Interacts with Parkin to Facilitate Myonuclear Positioning (A) In a wild-type larval muscle, myonuclear positioning is facilitated by the interaction of Ari-1 and Parkin, members of E3 ubiquitin ligase family, which regulate ubiquitination and turnover of Koi, one component of the LINC complex (Tan et al., 2018). (B) In an ari-1 null larval muscle, Parkin forms a dimer and is able to partially regulate myonuclear positioning. (C) In larvae with a missense mutation in ari-1, mutant Ari-1 binds strongly to Parkin—and perhaps to more than one Parkin—hindering the ability of both Ari-1 and Parkin to ubiquitinate Koi. This results in aberrant myonuclear positioning, nuclear clustering, and defective nuclear morphology.
  • Balakrishnan M, Baylies MK

  • Dev Cell. 2018 Apr 23;45(2):149-150.

2018-06-28

Fig 1. Peripheral blood white blood cell, absolute neutrophil, and CD34 cell counts. There is a trend of increasing white blood cell count (WBC, P=0.05) and absolute neutrophil count (ANC, P=0.03), but not CD34 concentration (P=0.65) with increasing dose of plerixafor.

Fig 1. Peripheral blood white blood cell, absolute neutrophil, and CD34 cell counts. There is a trend of increasing white blood cell count (WBC, P=0.05) and absolute neutrophil count (ANC, P=0.03), but not CD34 concentration (P=0.65) with increasing dose of plerixafor.
  • Boulad F, Shore T, van Besien K, Minniti C, Barbu-Stevanovic M, Fedus SW, Perna F, Greenberg J, Guarneri D, Nandi V, Mauguen A, Yazdanbakhsh K, Sadelain M, Shi PA

  • Haematologica. 2018 May;103(5):770-777.
Open Access button

2018-06-29

Fig 1. Protein structure visualization of SPOP mutations in the MSK-IMPACT study in the cBioPortal. The mutations were plotted along the primary sequence (up left); alignments from primary sequence to PDB chains were plotted underneath (bottom left); the protein structure of the selected alignment was displayed with mutations highlighted in the structure (right).

Fig 1. Protein structure visualization of SPOP mutations in the MSK-IMPACT study in the cBioPortal. The mutations were plotted along the primary sequence (up left); alignments from primary sequence to PDB chains were plotted underneath (bottom left); the protein structure of the selected alignment was displayed with mutations highlighted in the structure (right).
  • Wang J, Sheridan R, Sumer SO, Schultz N, Xu D, Gao J

  • Bioinformatics. 2018 Jun 1;34(11):1949-1950.